The HER2 gene is altered in more than 10% of advanced gastric cancers, and trastuzumab is the only approved drug that can target HER2, thus being used as a first-line standard treatment option for advanced HER2-positive gastric cancer (13–15). The gene discussed is ERBB2; the disease is gastric cancer.